Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide.
Kaneto
Hideaki
H
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. kaneto@medone.med.osaka-u.ac.jp
Nakatani
Yoshihisa
Y
Miyatsuka
Takeshi
T
Kawamori
Dan
D
Matsuoka
Taka-aki
TA
Matsuhisa
Munehide
M
Kajimoto
Yoshitaka
Y
Ichijo
Hidenori
H
Yamasaki
Yoshimitsu
Y
Hori
Masatsugu
M
D000595:Amino Acid Sequence; D000818:Animals; D015153:Blotting, Western; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D016650:Fluorescein-5-isothiocyanate; D015316:Genetic Therapy; D047468:Immunoprecipitation; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D048055:Mitogen-Activated Protein Kinase 8 / Q000037:antagonists & inhibitors*; D008969:Molecular Sequence Data; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014162:Transfection
D010455:Peptides; D048055:Mitogen-Activated Protein Kinase 8; D016650:Fluorescein-5-isothiocyanate